FcγRIIB specific antibodies and methods of use thereof
First Claim
1. A method of enhancing immune response to an antigen in a patient by blocking negative regulation of immune-complex-triggered activation, wherein said antigen is associated with a cancer or a neoplastic disease or is an antigen of a pathogen, said method comprising administering to said patient:
- (i) an antigen-antibody complex; and
(ii) an antibody or an antigen-binding fragment thereof that specifically binds the extracellular domain of human Fcγ
RIIB with greater affinity than human Fcγ
RIIA and inhibits binding to the Fc binding site of human Fcγ
RIIB, wherein said antibody or antigen-binding fragment thereof comprises the six CDRs of antibody produced by clone 2B6 having ATCC Accession No. PTA-4591 or the six CDRs of antibody produced by clone 3H7 having ATCC Accession No. PTA-4592;
to thereby enhance immune response in said patient to said antigen.
1 Assignment
0 Petitions
Accused Products
Abstract
The present invention relates to antibodies or fragments thereof that specifically bind the extracellular domain of FcγRIIB, particularly human FcγRIIB, and block the Fc binding site of human FcγRIIB. The invention provides methods of treating cancer and/or regulating immune complex-mediated cell activation by administering the antibodies of the invention to enhance an immune response. The invention also provides methods of breaking tolerance to an antigen by administering an antigen-antibody complex and an antibody of the invention.
-
Citations
16 Claims
-
1. A method of enhancing immune response to an antigen in a patient by blocking negative regulation of immune-complex-triggered activation, wherein said antigen is associated with a cancer or a neoplastic disease or is an antigen of a pathogen, said method comprising administering to said patient:
-
(i) an antigen-antibody complex; and (ii) an antibody or an antigen-binding fragment thereof that specifically binds the extracellular domain of human Fcγ
RIIB with greater affinity than human Fcγ
RIIA and inhibits binding to the Fc binding site of human Fcγ
RIIB, wherein said antibody or antigen-binding fragment thereof comprises the six CDRs of antibody produced by clone 2B6 having ATCC Accession No. PTA-4591 or the six CDRs of antibody produced by clone 3H7 having ATCC Accession No. PTA-4592;to thereby enhance immune response in said patient to said antigen. - View Dependent Claims (2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16)
-
Specification